Puma Biotechnology Inc: stock overview

PBYINASDAQHealthcare · Pharmaceutical Preparations

Price

$7.77

November 13, 2026Market cap $395M

DCF calculator

What Ploutos Investor adds for Puma Biotechnology

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 9 fiscal years, from 2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Puma Biotechnology had revenue of $232M over the last 12 months and net income of $24M, a net margin of 10.3%. Revenue grew by 0.3% a year on average over the last 5 years. At $7.77 the shares trade at a P/E of 16.6, against a median of 9.6 over the last 3 fiscal years. It holds more cash than debt, by $55M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$395M
50.88M shares
P/E
16.6
Today16.6
Median9.6
Revenue, 12 months
$232M
+0.3% a year over 5 years
Net margin
10.3%
2025: 13.6%, above 81% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

-1.6% a year over 2 years

  • 202510-K
    Revenue$228M
  • 202410-K
    Revenue$230M
  • 202310-K
    Revenue$236M

Fiscal years in figures

PBYI's revenue, profit, cash flow and dividend with each year-end price, from 2017 to 2022, 6 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $209M
$395M
Enterprise value 
$340M
P/E 3-year median: 9.6
16.6
EV / EBIT 
13.0
EV / Revenue 
1.5
P/B 3-year median: 2.3
2.7
FCF yield 3-year median: 13.8%
11.6%
Earnings yield 3-year median: 10.4%
6.0%

Profitability

Gross margin 
73.6%
Operating margin 
11.3%
Net margin 3-year median: 13.1%
10.3%
ROIC 
12.8%
ROIC, 5-year average 
13.6%
ROE 
18.1%

Growth

Revenue, yearly change 
-0.9%
EPS, yearly change 
-1.6%
FCF, yearly change 
+7.4%
Revenue, average a year 
+0.3%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$101M
Total debt 
$50M
Of which operating leases 
$4.9M
Net cash 
$55M
Net debt / EBITDA 
-1.5x
Interest cover 
12.9x
Current ratio 
3.03

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+2.6%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

16.3%

Above 80% of the 285 companies in its industry, and 77% of all.

Net margin

13.6%

Above 81% of the 302 companies in its industry, and 73% of all.

ROE

23.9%

Above 85% of the 267 companies in its industry, and 88% of all.

ROA

14.4%

Above 87% of the 313 companies in its industry, and 94% of all.

Revenue growth

-0.9%

Above 32% of the 292 companies in its industry, and 26% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
PUMA BIOTECHNOLOGY, INC.
CIK
1401667
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
50.88M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Puma Biotechnology's filings show?

These are Puma Biotechnology's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about PBYI

Didn't find what you were looking for?

Ask us
What is PBYI's market cap?

Puma Biotechnology Inc's market cap is $395M, at a price of $7.77 on November 13, 2026 and 50.88M shares.

What is PBYI's P/E?

PBYI's P/E is 16.6, on earnings per share of $0.46 over the last 12 months. The median over the last 3 fiscal years was 9.6.

How much revenue does PBYI have?

Puma Biotechnology had revenue of $232M over the last 12 months. Over the last 5 years it changed by +0.3% a year on average.

Does PBYI pay a dividend?

No. Puma Biotechnology paid no regular dividend over the last 12 months.

Where do the figures come from?

From Puma Biotechnology Inc's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.